(-0.05%) 5 476.00 points
(-0.07%) 38 791 points
(-0.02%) 19 918 points
(0.29%) $80.56
(1.15%) $2.82
(0.24%) $2 334.60
(-0.12%) $29.36
(-0.20%) $969.00
(0.01%) $0.932
(-0.15%) $10.64
(0.05%) $0.788
(-1.87%) $86.80
Live Chart Being Loaded With Signals
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders...
Stats | |
---|---|
Šios dienos apimtis | 2.42M |
Vidutinė apimtis | 2.15M |
Rinkos kapitalizacija | 79.65M |
EPS | $-0.680 ( Q1 | 2024-05-08 ) |
Kita pelno data | ( $-0.590 ) 2024-08-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.550 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00800 (0.55%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-27 | Braunstein Scott | Buy | 50 000 | Common Stock |
2024-03-27 | Braunstein Scott | Sell | 50 000 | Stock Option (Right to Buy) |
2024-02-20 | Shafer Christina | Sell | 2 153 | Common Stock |
2024-02-20 | Manning Martha E | Sell | 1 894 | Common Stock |
2024-02-16 | Hulihan Joseph | Sell | 2 814 | Common Stock |
INSIDER POWER |
---|
88.76 |
Last 96 transactions |
Buy: 2 669 285 | Sell: 293 774 |
Tūris Koreliacija
Marinus Pharmaceuticals Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
MBIO | 0.955 |
ALLR | 0.947 |
ZD | 0.938 |
APVO | 0.936 |
PERI | 0.935 |
HOFT | 0.933 |
ISSC | 0.929 |
MPAA | 0.927 |
POAI | 0.925 |
INVE | 0.921 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
GRIN | -0.964 |
ABIO | -0.948 |
CSTE | -0.945 |
GALT | -0.941 |
NKTR | -0.935 |
GAIA | -0.935 |
SLAM | -0.929 |
AMRK | -0.928 |
PPTA | -0.927 |
SGRP | -0.927 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Marinus Pharmaceuticals Koreliacija - Valiuta/Žaliavos
Marinus Pharmaceuticals Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $30.99M |
Bruto pelnas: | $28.50M (91.98 %) |
EPS: | $-2.63 |
FY | 2023 |
Pajamos: | $30.99M |
Bruto pelnas: | $28.50M (91.98 %) |
EPS: | $-2.63 |
FY | 2022 |
Pajamos: | $25.48M |
Bruto pelnas: | $25.14M (98.67 %) |
EPS: | $-0.510 |
FY | 2021 |
Pajamos: | $15.35M |
Bruto pelnas: | $13.87M (90.37 %) |
EPS: | $-2.69 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, tuberous sclerosis complex, depressive disorders, and Lennox-Gestaut Syndrome. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.